Illumina CEO envisions stable growth despite uncertainty
- DNA writer
- Aug 29, 2025
- 1 min read
Illumina CEO Jacob Thaysen remains confident in the company’s growth despite recent challenges, including a ban on selling DNA sequencers in China and disruptions to academic labs. He projects a slight revenue dip of 0.5%–2.5% for the current year but expects high single-digit revenue growth by 2027. Increased funding from the NIH could help alleviate financial pressures on academic customers, supporting ongoing demand for Illumina’s sequencing technology.
Looking ahead, Thaysen outlined a strategic shift toward expanding Illumina’s offerings beyond genomics into areas like epigenetics and proteomics. This multiomics approach aims to provide deeper biological insights and broaden the company’s market reach, reflecting a focus on innovation and adaptability in the evolving landscape of research and healthcare.
Read more